



James M. Olson, MD, PhD
Full Member, Fred Hutchinson Cancer Research Center

Dr. Olson cares for children and young adults with brain cancer and led a 16-20 person research laboratory that focuses on translational brain tumor research. He founded two biotechnology companies based on inventions and research conducted by his team. His laboratory has conducted over 40 full scale pre-clinical drug efficacy studies in clinically relevant mouse models and has generated 26 mouse models of brain cancer. He has translated laboratory findings into four national human clinical trials, of which he is the chair of a Phase III study and co-Chair of a Phase II study and an Infant Brain Tumor Trial. His lab developed a technology platform that enables multiplexed *in vivo* analyses of tumor pathway perturbation by RNAi or drugs. This is being commercialized by Presage Biosciences and is being used by several of the leading pharmaceutical companies for oncology pipeline prioritization. His team also invented Tumor Paint, which following IV administration, causes cancer cells to light up with near infrared fluorescent signal to aid surgeons in achieving complete surgical resections for patients with cancer. This is being advanced to the FDA and commercialized by Blaze Bioscience: The Tumor Paint Company. Dr. Olson earned a Ph.D. in Pharmacology and an MD at the University of Michigan and he completed Pediatrics and Pediatric Oncology training at the University of Washington (UW). He is currently on faculty at the UW, Fred Hutchinson Cancer Research Center, and Seattle Children's Hospital.